Why Biohaven (BHVN) Is Up 25.0% And What's Next After FDA Review Acceptance

Biohaven secured FDA acceptance of its resubmitted new drug application for Vyglxia, or troriluzole, in spinocerebellar ataxia, with a planned advisory committee review and a user fee goal date set in Q1 2027. The firm also signed a licensing and collaboration deal with Ono Pharmaceutical for its MoDE pan IgG degrader portfolio in select Asian markets. This supports funding and regional execution for programs such as BHV-1300 for Graves' disease. The focus now shifts to how Biohaven's...